Solventum (NYSE:SOLV) Stock Rating Lowered by Wall Street Zen

Solventum (NYSE:SOLV) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Several other research firms have also weighed in on SOLV. Wells Fargo & Company lowered their price objective on shares of Solventum from $86.00 to $83.00 and set an “equal weight” rating for the company in a research note on Friday, February 27th. Stifel Nicolaus upped their price objective on shares of Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Zacks Research downgraded Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. Finally, Piper Sandler reissued an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $93.70.

Solventum Stock Down 1.3%

Shares of NYSE SOLV opened at $68.51 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. Solventum has a 1 year low of $60.70 and a 1 year high of $88.20. The company has a 50 day simple moving average of $77.39 and a 200 day simple moving average of $76.18. The firm has a market cap of $11.89 billion, a PE ratio of 7.72, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.96 billion. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The firm’s revenue was down 3.7% compared to the same quarter last year. During the same period last year, the company earned $1.41 earnings per share. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, research analysts forecast that Solventum will post 6.58 EPS for the current year.

Solventum announced that its board has approved a share repurchase plan on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 7.5% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its stock is undervalued.

Institutional Trading of Solventum

Several institutional investors and hedge funds have recently made changes to their positions in the company. Corient Private Wealth LLC boosted its holdings in Solventum by 18.5% during the fourth quarter. Corient Private Wealth LLC now owns 49,092 shares of the company’s stock worth $3,859,000 after purchasing an additional 7,653 shares during the last quarter. Hsbc Holdings PLC boosted its stake in shares of Solventum by 2.3% in the 4th quarter. Hsbc Holdings PLC now owns 227,139 shares of the company’s stock worth $18,021,000 after buying an additional 5,015 shares during the last quarter. Bayban bought a new position in shares of Solventum in the fourth quarter valued at approximately $134,000. Caitong International Asset Management Co. Ltd increased its position in shares of Solventum by 80.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 429 shares of the company’s stock valued at $34,000 after acquiring an additional 191 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in Solventum by 28.2% during the fourth quarter. Pacer Advisors Inc. now owns 17,149 shares of the company’s stock worth $1,359,000 after acquiring an additional 3,768 shares during the period.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.